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Abstract
Background: Given the increasing evidence of Plasmodium vivax infections associated with severe and fatal disease, the
identification of sensitive and reliable markers for vivax severity is crucial to improve patient care. Circulating nucleic acids
(CNAs) have been increasingly recognized as powerful diagnostic and prognostic tools for various inflammatory diseases
and tumors as their plasma concentrations increase according to malignancy. Given the marked inflammatory status of P.
vivax infection, we investigated here the usefulness of CNAs as biomarkers for malaria morbidity.
Methods and Findings: CNAs levels in plasma from twenty-one acute P. vivax malaria patients from the Brazilian Amazon
and 14 malaria non-exposed healthy donors were quantified by two different methodologies: amplification of the human
telomerase reverse transcriptase (hTERT) genomic sequence by quantitative real time PCR (qPCR), and the fluorometric
dsDNA quantification by Pico Green. CNAs levels were significantly increased in plasma from P. vivax patients as compared
to healthy donors (p,0.0001). Importantly, plasma CNAs levels were strongly associated with vivax morbidity (p,0.0001),
including a drop in platelet counts (p=0.0021). These findings were further sustained when we assessed CNAS levels in
plasma samples from 14 additional P. vivax patients of a different endemic area in Brazil, in which CNAS levels strongly
correlated with thrombocytopenia (p=0.0072). We further show that plasma CNAs levels decrease and reach physiological
levels after antimalarial treatment. Although we found both host and parasite specific genomic sequences circulating in
plasma, only host CNAs clearly reflected the clinical spectrum of P. vivax malaria.
Conclusions: Here, we provide the first evidence of increased plasma CNAs levels in malaria patients and reveal their
potential as sensitive biomarkers for vivax malaria morbidity.
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Introduction
Plasmodium vivax malaria threatens almost 40% of the world’s
population, with an upper estimate of 300 million cases each year
[1]. Fortunately, after a long time being neglected under the
contemptible designation of benign infection, vivax malaria has
gained increasing attention in recent years.
In the last decade, a series of case reports and longitudinal
studies carried out in India [2,3], Papua in Indonesia [4,5], Papua
New Guinea [6] and Brazil [7] have demonstrated association of
P. vivax infections with severe or even fatal outcomes, with
incidence and morbidity rates similar to those for P. falciparum.
Consequently, costs due to hospitalization have significantly raised
as well as the need for intensive care, which helped vivax malaria
to be placed in a higher status of public health emergency [7].
Compared to falciparum malaria, there are remarkably large
knowledge gaps in the pathophysiology of vivax malaria, and the
true spectrum of clinical disease in endemic areas remains
unknown [8]. The few studies that have addressed the pathogen-
esis of vivax malaria showed that the different clinical presenta-
tions of vivax malaria might be related to the intensity of pro-
inflammatory responses [9,10,11,12]. Inflammatory cytokines such
as TNF-alpha and antioxidant agents have been associated with
clinical severity of P. vivax infections [13,14]. Nevertheless, data
validating their sensitivity and reliability as predictors of severe
disease are scarce. Consequently, the identification of highly
sensitive biomarkers for malaria vivax morbidity is crucial to
prevent life threatening complications.
Most of the DNA and RNA in the human body are located
within cells, but small physiologic amounts of nucleic acids can
also be found circulating freely in the blood. These DNA, RNA,
and small RNA molecules may arise from both: i) active release of
nucleic acids from living cells, or ii) break down of dying cells that
release their contents into the blood. The term Circulating Nucleic
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19842Acids (CNAs) refers to cell free segments of DNA or RNA found in
the bloodstream. Their existence in human plasma was first
reported more than 60 years ago [15], however, no interest was
shown in the presence of DNA in the circulatory system until high
DNA levels were demonstrated in the blood of patients with
cancer [16]. Elevated plasma CNAs levels have now been detected
during other acute illnesses and injuries. Examples include lupus
erythematosus [17,18], diabetes [19], trauma [20], stroke [21],
and myocardial infarction [22,23]. Furthermore, high usefulness of
CNAs levels in the diagnosis of infections in febrile patients and as
a prognostic marker in septic patients has been shown [24]. Their
applications in clinical diagnosis and prognosis have continuously
grown and further studies on CNAs showed that these nucleic
acids could be a powerful non-invasive approach to a wide range
of clinical disorders [25].
Aiming at finding sensitive and reliable biomarkers for P. vivax,
herein we tested the usefulness of plasma CNAs levels as markers
for the morbidity of vivax malaria. We investigated the CNAs
levels in plasma from P. vivax infected patients with different
clinical presentations and found significant higher levels of CNAs
in P. vivax infected patients, as compared to age-matched healthy
donors. We found that plasma CNAs levels were closely correlated
with variations in body temperature, platelets counts, and
increased in a linear fashion with the clinical spectrum of vivax
malaria, evaluated here by scoring patients’ clinical and
hematological parameters.
Results
CNAs levels were measured in plasma from P. vivax patients by
qPCR amplification of the genomic sequence of the human single
copy gene hTERT and by fluorometric quantification of the
dsDNA content with the Quant-iT
TM Pico Green Reagent. The
amplification plot of hTERT shows that the mean cycle threshold
(Ct) achieved in CNAs samples from P. vivax patients (mean Ct
28.661.5) was significantly lower than the one reached in samples
from healthy donors (mean Ct 31.560.79) (p,0.0001) (Fig. 1A
and 1C). As the amount of DNA theoretically doubles every cycle
during the exponential phase of qPCR, these results suggest that
the levels of this target sequence in the CNAs preparation from P.
vivax patients are at least 8-fold higher than in healthy donors. In
fact, a difference of 11,66 between the hTERT levels in plasma
from P. vivax patients (1.278 pg/ml) and healthy donors
(0.1098 pg/ml) was confirmed when a standard curve, built from
a serial dilution of an amplified sample of hTERT sequence, was
used to interpolate the hTERT concentrations in the samples
(Figure S1). To normalize the amount of nucleic acids purified and
inputted in qPCR experiments, 5 ng of salmon sperm DNA was
Figure 1. Increased CNAs levels in plasma from P. vivax patients. CNAs levels were quantified in plasma from acute P. vivax patients or
healthy donors by measuring the amplification of the hTERT human genomic sequence (A) as compared to the amplification of the O. keta Y
chromosome marker (B) for the salmon sperm DNA spiked into plasma samples before CNAs purification. (C) Comparison of the mean cycle threshold
(Ct) from the hTERT or the O. keta Y chromosome marker in CNAs samples purified from P. vivax patients or non-exposed healthy donors. (D)
Fluorometric dsDNA quantification of CNAs levels in plasma by the Quant-iT
TM Pico Green methodology. Statistical analyses were performed using
the Mann-Whitney test. A p value,0.05 was considered significant.
doi:10.1371/journal.pone.0019842.g001
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expected, the specific sequence of salmon sperm DNA was
similarly amplified in P. vivax patients and healthy donors plasmas
(Fig. 1B and 1C, p=0.6925).
The increased levels of total CNAs in plasma from P. vivax
patients were confirmed by quantification of dsDNA with Quant-
iT
TM Pico Green Reagent (Fig. 1D) (1494.761169.7 in vivax
patient vs. 689.036131.54 pg/ml in healthy donors, p,0.0001).
To investigate the potential of CNAs as biomarkers for malaria
morbidity, we compared the levels of CNAs in plasma from
patients with different clinical presentations, and scored according
to clinical and hematological parameters (Table S1). Figure 2A
illustrates the qPCR amplification of the hTERT genomic
sequence in plasma from four P. vivax patients and four
unexposed-controls. Sensitive changes in hTERT amplification
were observed according to the slightest increase in the clinical
score. Furthermore, significantly higher levels of CNAs were found
in plasma isolated from patients who presented fever at the time of
blood collection (febrile patients) compared to plasma samples
from non-febrile patients, as revealed by the two different
methodologies: amplification of hTERT genomic sequence by
qPCR (p=0.0376) and the quantification of dsDNA content with
Quant-iT
TM Pico Green (p=0.0023) (data not shown).
To confirm whether CNAs levels reflect disease morbidity, the
sum of scores attributed to each patient (Table S1) was plotted
against the CNAs levels detected in plasma with the Quant-iT
TM
Pico Green or the mean cycle threshold detected by qPCR
amplification of the hTERT genomic sequence (Fig. 2B). A clear
correlation (Spearman r=0.4795, p=0.0034) was found between
the CNAs levels and the intensity of clinical malaria. These data
were confirmed when the Cts from the amplification of hTERT
were analyzed (Pearson r=20.7111, p,0.0001) (Fig. 2B).
Platelet activation exerts thrombotic and pro-inflammatory
functions and their unbalanced activation contributes to life-
threatening outcomes in diseases such as heart attack, stroke, and
cancer [26]. Both platelets [27] and platelet derived microparticles
(PMPs) [10] have been associated with clinical manifestations of
malaria. We thus investigated if plasma CNAs levels may be
associated with thrombocytopenia and/or others hematological
parameters, such as WBC and RBC counts, hemoglobin and
hematocrit levels, mean corpuscular hemoglobin (MHC) and
mean platelet volume (MPV). Among all parameters investigated,
we found a strong negative correlation between CNAs levels,
assessed by dsDNA quantification with Pico Green, and platelet
counts (spearman r=20.6451, p=0.0021) (Fig. 3A). These
findings were confirmed when the mean Ct obtained after qPCR
amplification of the genomic sequence for hTERT gene was
plotted against platelet levels (Pearson r=0.6479, p=0.0027)
(Fig. 3B).
To further confirm the association between CNAS levels and P.
vivax morbidity, we assessed the CNAS levels in plasma from an
additional group of P. vivax patients whose selection was carried-
out in a different hospital of the Amazon area, Cuiaba, MT
(,1500 miles from Manaus, AM). Once the clinical protocol used
at the hospital in Cuiaba was different from Manaus (FMT-HVD),
we were unable to build a similar clinical score. For this reason, we
compared the CNAS levels in these samples with thrombocyto-
penia, a common hematological disturbance seen in malaria
morbidity in the Amazon area [28]. By analyzing the amplification
of hTERT, it was possible to demonstrate a significant correlation
(Pearson r=0.745, p=0.0072) between CNAS levels and
thrombocytopenia in P. vivax patients from Cuiaba (Figure S2A).
As this study provides the first description of circulating nucleic
acids in malaria infection, we evaluate CNAs levels in a small group
of P. falciparum patients who sought for care at Cuiaba’s hospital
(n=9). CNAs levels were significantly higher in samples from
falciparum malaria patients as compared to healthy donors
(p=0.038; not shown). Importantly, CNAs levels in patient’s plasma
clearly correlated with thrombocytopenia (Figure S3A) and the
occurrence of fever during acute P. falciparum infection (Figure S3B).
Figure 2. Plasma CNAs levels reliably correlate with the P. vivax clinical spectrum. CNAs levels were quantified in plasma from P. vivax
patients with different clinical presentations. (A) Amplification of the genomic sequence of hTERT by qPCR in four healthy controls, and P. vivax
patients (Pv_01 to 04) scored according to clinical/hematological parameters. Only four patients are shown for illustration purposes. (B) Correlation
between the final clinical score of P. vivax patients (n=21) and their plasma CNAs levels (pg/ml) (Spearman r=0.6092, p=0.0034), or their Ct for the
amplification of the hTERT (Pearson r=20.7897, p,0.0001).
doi:10.1371/journal.pone.0019842.g002
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CNAs levels were further assessed 7 days after antimalarial
chemotherapy. As shown in Fig. 4A, CNAs levels decreased after
specific treatment (p=0.0428). The comparison of the mean Ct
obtained after qPCR amplification of the hTERT in plasma
samples from acute vs. treated patients confirmed these findings
(p=0.0243) (Fig. 4B). Seven days post-treatment, the platelet
counts returned to physiological levels (Fig. 4C). These data were
further confirmed in patients from Cuiaba area (n=10) (Figure
S2B). In those samples, CNAs levels were significantly diminished
after 7–10 days of chemotherapy.
It is reasonable to speculate that parasite specific DNA is present
among the CNAs circulating in plasma. To confirm this, we
assessed the levels of P. vivax derived-CNAs in plasma in an
attempt to investigate their use as a streamline diagnostic and
prognostic tool. For this purpose, specific primers were designed to
amplify a genomic sequence unique to P. vivax. As expected,
amplification of this genomic sequence was not detected in
samples from healthy donors (Fig. 5A). Furthermore, although
parasite specific CNAs levels were weakly associated with the
presence of fever at the time of blood sampling (Ct vs. body
temperature, r=20.5535, p=0.0497) (Fig. 5B), they were not
Figure 3. Correlation between plasma CNAs levels and malaria vivax thrombocytopenia. Correlation of plasma CNAs levels with platelet
counts in symptomatic vivax malaria patients. The dsDNA levels measured by Pico Green (A) and the mean cycle threshold for hTERT amplification (B)
were plotted against the platelet counts. Spearman (r=20.6451) and Person (r=0.6479) correlations were used respectively in A and B. A p
value,0.05 was considered significant.
doi:10.1371/journal.pone.0019842.g003
Figure 4. Plasma CNAs levels decrease after anti-malarial chemotherapy. For 6 patients who showed up during convalescence, the CNAs
levels in plasma were assessed by (A) fluorescence quantification of dsDNA with the Pico Green methodology or (B) comparison of the mean cycle
threshold for the qPCR amplification of hTERT genomic sequence. (C) platelet counts measured during admission and convalescence. Statistics were
performed as follow: Mann-Whitney test for panel A, and two tailed t test for panels b and C. A p value,0.05 was considered significant.
doi:10.1371/journal.pone.0019842.g004
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p=0.2056) (Fig. 5C). Also, parasite specific CNAs genomic
sequences did not reflect peripheral parasitemia (r=20.3735,
p=0.1884).
Discussion
This study is the first to investigate the use of plasma levels of
cell-free circulating nucleic acids (CNAs) as a marker of P. vivax
malaria morbidity. We show here that CNAs levels in plasma from
P. vivax patients increase linearly with the clinical spectrum of the
disease. This confirms that this powerful marker can also be used
in malaria as a sensitive indicator of inflammation and injury. In
fact, plasma CNAs levels have been regarded as a noninvasive
universal cancer biomarker [29] as their levels have been shown to
be distinctly increased in most patients with solid tumors (E.g. lung
[30], colon [31], cervical [32], ovarian [33], breast [34], testis [35],
bladder [36], and prostate [37]), allowing their discrimination
from patients with nonmalignant disease or healthy individuals.
Plasma CNAs levels have also been associated with the severity of
several other inflammatory disorders [17,18,19,20,21,22,23].
Other molecules circulating in plasma, such as adhesion
molecules [38], pro-inflammatory cytokines [39], the superoxide
dismutase-1 [14], and, more recently, microparticles [10], have
been suggested as biomarkers for human P. vivax malaria as their
levels are often associated with malaria clinical manifestations.
Nevertheless, we believe that CNAs offer a more sensitive tool
since qPCR amplification of hTERT, a specific single copy human
genomic sequence, revealed that levels as low as 100 fentogram of
CNAs could be detected circulating in plasma, and were able to
discriminate different degrees of disease morbidity (Figure S1).
We show here that plasma CNAs reach physiologic levels after
7–10 days of antimalarial chemotherapy and patient’s recovery. It
has been shown that clearance of cell-free DNA from the
bloodstream occurs rapidly; the half-life time of fetal DNA in
the blood of mothers after delivery was approximately 16 minutes
[40]. Cell-free DNA seems to be eliminated by different manners
including renal and hepatic mechanisms as well as degradation by
plasma nucleases [29]. It is unknown whether a different clearance
time is also contributing to the higher levels of cell-free DNA in
malaria patients. The kinetics by which CNAs levels rise and fall
during acute malaria requires further investigation.
The source of CNAs levels during malaria remains unknown.
Apoptosis and necrosis have been pointed as the main source of
cell-free DNA circulating in blood [41,42]. Usually apoptosis-
induced cleavage of DNA results in DNA fragments of
approximately 180 bp; thus, quantification of a small and a long
PCR product allows indirect inferences about the underlying cell-
death entity. Although apoptosis has not been directly addressed in
this study, our results do not rule out this possibility, as most of the
fragments amplified were in the range of 90 bp to be suitable for
qPCR analysis. In malaria, apoptosis is a process highly
represented in the annotation of gene expression profile of acute
infection as revealed by several microarray studies involving both
human and mouse models [43,44]. Nevertheless, it was recently
shown that apoptosis and or necrosis might not be the main
sources of CNAs in plasma of patients with a variety of other
conditions, and active release of free circulating DNA by living
cells was pointed as a plausible mechanism [45]. At this time, it is
unknown whether apoptosis and/or DNA release contribute to the
higher levels of cell-free DNA observed here in P. vivax patients.
Thrombocytopenia (platelet counts ,150,000/mm
3)i sa
common hematological finding in patients with Plasmodium
infection particularly in vivax malaria [28,46]. Recent studies
carried out in northwest India highlighted the higher occurrence
of severe thrombocytopenia in P. vivax in comparison to either P.
falciparum monoinfection or mixed infections [47,48]. We show
here that CNAs levels in vivax malaria strongly correlate with a
drop in platelet counts, a data confirmed in two different hospitals
of the Amazon area. Although it is not possible, at this point, to
speculate on the role of platelets in the increase of CNAs levels in
plasma, our results indicate that CNAs might contribute to cell
activation and inflammation that are associated with malaria
infection.
Although P. falciparum infection was not the main scope of the
present study, by having access to a small group of patients, it was
possible to demonstrate that CNAS levels are increased during
acute P. falciparum infection. In this malaria model, increased
CNAs levels in plasma were associated with thrombocytopenia
and the occurrence of fever at the time of blood collection (Figure
Figure 5. Plasmodium specific genomic sequences circulating in plasma from P. vivax patients. The presence and levels of P. vivax specific
plasma CNAs were investigated in samples from P. vivax patients with different clinical presentations by qPCR amplification of a specific P. vivax
genomic sequence. (A) For illustration purpose, qPCR amplification of a P. vivax specific genomic sequence in four healthy controls, and four P. vivax
patients (Pv_01 to 04) scored according to clinical/hematological parameters is shown. (B) Pearson correlation between the Ct of parasite specific
genomic sequence and the body temperature measured at the time of blood collection (r=20.5535, p=0.0497) or the clinical score of the patients
(r=20.3604, p=0.2056). A p value,0.05 was considered significant.
doi:10.1371/journal.pone.0019842.g005
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and malaria, the size of our sample precludes any definitive
comparison between P. falciparum and P. vivax infection. Further
studies will be required to proper address this question.
In uncomplicated P. vivax malaria, we have recently shown that
the levels of circulating platelet-derived microparticles (PMPs) are
associated with the clinical spectrum of disease, including fever
and prolonged time with malaria symptoms [10]. The fact that
CNAs levels as well as PMPs were higher in febrile and
symptomatic vivax patients suggests a possible association with
PMP and CNAs. MPs are important carriers of membrane
components or bioactive molecules and their association with
nucleic acids has been proposed [49]. The presence of host and/or
parasite DNA associated with MPs circulating in plasma and their
role in inflammation is currently being addressed in your
laboratory.
To investigate if parasite derived-sequences are part of the pool
of nucleic acids circulating in blood during vivax malaria, and if
these sequences correlate with disease morbidity, we assessed the
levels of a parasite specific single copy genomic sequence in CNAs
purified from P. vivax patients. Although our results revealed that
host and parasite sequences are part of the total plasma CNAs
levels in acute P. vivax infected patients, the levels of a host specific
(hTERT) but not parasite specific sequence correlated with vivax
clinical disease. These results are in agreement with a recently
study carried out in the Amazon area in which high parasitemia
was not the rule among patients with severe disease according to
the WHO criteria [50].
Whether CNAs are merely inert debris of cellular injury, or if
they possess pro-inflammatory properties and are, therefore,
players in the immunopathogenic basis of malaria requires further
investigation. Although at this point is not possible to draw
conclusions, their role in the inflammatory response during
malaria cannot be rule out. In fact, it is well known that dying
cells spill their content and release a myriad of endogenous pro-
inflammatory danger signals, including proteins, nucleic acids,
extracellular matrix components, lipid mediators and adenosine
triphosphate (ATP) [51]. These endogenous danger signals have
been shown to play important roles in inflammation [51,52,53]. As
human and parasite derived nucleic acid sequences have been
shown to posses immune-stimulatory properties, the implication of
CNAs in cellular activation and in innate immunity is likely.
Likewise, the frequency of immune stimulatory vs. non-stimulatory
circulating nucleic acids in plasma from patients with different
clinical outcomes would provide important insights into the role of
CNAS in malaria pathogenesis.
In conclusion, we show that host circulating nucleic acids in
plasma constitute a reliable and non-invasive biomarker to
evaluate vivax malaria morbidity. CNAs levels were closely
associated with P. vivax malaria clinical spectrum, and may have
a role in malaria-induced inflammation. Given the enormous
economic scourge of P. vivax in endemic areas, plasma CNAs levels
provide a welcome prognostic tool to rapidly identify potentially
severe cases and improve clinical management.
Materials and Methods
Study area and subjects
This study was conducted in May 2010, at Fundac ¸a ˜o de
Medicina Tropical Dr. Heitor Vieira Dourado (FMT-HVD), a
tertiary care center for infectious diseases in Manaus (3u89S,
60u19W), the capital of the state of Amazonas, Brazil. Manaus is
clearly part of a new frontier in the economic development of the
Amazon and is considered as one of the leading cities in terms of
number of P. vivax malaria cases in Latin America [54]. In 2009, a
total of 19,698 malaria cases were reported in Manaus with a large
dominance of vivax (92.6%) over falciparum malaria [55].
Individuals who sought care at FTM-HVD and whose thick
blood smear was positive for P. vivax were invited to participate in
the study. Exclusion criteria included: (i) refuse or inability to sign
the informed consent; (ii) age ,18 years; (ii) pregnant women; (ii)
mixed infection with P. falciparum or P. malariae; (iv) any other co-
morbidity that could be traced. Twenty-one patients, aging 21 to
72 years, were enrolled in the study. Selected volunteers were all
negative for P. falciparum and/or Plasmodium malariae infection by
both microscopic examination and a nested-PCR, carried out
latter in our laboratory. Clinical and demographical data were
acquired through a standardized questionnaire, and the hemato-
logical profiles were assessed by automated complete blood count
carried out at FMTA hematology facility. Table 1 summarizes
demographic, epidemiological, parasitological and hematological
data of P. vivax infected-volunteers.
The study was approved by the Ethical Review Board of the
Rene ´ Rachou Research Center, FIOCRUZ, Brazilian Ministry of
Health (Reporter CEPSH/CPqRR 05/2008). All participants
were instructed about the objectives of the study and signed an
Table 1. Characteristics of the Plasmodium vivax patients
enrolled in the study.
CHARACTERISTICS
Demographical and epidemiological
Sex, male/female, proportion 13/8
Age, median, range 49 (21–72)
Nu of previous malaria episodes 3 (0–30)
Parasitological and hematological, median (range)
Parasitemia, parasites/ml of blood 305 (25–2255)
Hematocrit %, 42.6 (30.5–48.9)
Hemoglobin levels g/dL 13.2 (9.5–14.9)
WBC counts610
6/mm
3 4.9 (2–8.6)
RBC counts610
6/mm
3 4.8 (3.57–5.42)
Platelet counts610
6/mm
3 125.5 (39–225)
MCV (fL) 89.3 (82.9–96)
MPV (fL) 9.8 (8.1–13.2)
MCH (pg) 27.1 (25–30.1)
MCHC (g/dL) 30.6 (29.8–33.2)
Clinical parameters
Duration of symptoms in days, median, (range) 3 (.1–20)
Fever at the time of blood sampling, n (%) 7 (33.3%)
Symptoms in the last 3 days, n (%)
Fever 21 (100%)
Myalgia 21 (100%)
Chills 19 (90.5%)
Headache 18 (85.7%)
Nausea 15 (71.4%)
Anorexia 12 (57.1%)
Vomiting 6 (28.6%)
Dyspnea 6 (28.6%)
Diarrhea 3 (14.3%)
doi:10.1371/journal.pone.0019842.t001
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research, as specified by the Brazilian National Council of Health
(Resolution 196/96). Patients diagnosed with vivax malaria were
treated according to the standard protocols recommended by the
National Malaria Control Program (chloroquine plus primaquine).
Peripheral blood samples (10 mL in EDTA) were obtained from
patients on admission and, in those who attended follow-up,
during convalescence 7 days later. Plasma samples from 14 age-
matched malaria-unexposed donors from Belo Horizonte, a
malaria free area, were used as baseline control. Aiming to avoid
bias of selection, we further include an additional group of P. vivax
patients (n=14; age range, 18–41 years) from a second hospital of
the Amazon area, Julio Muller Hospital, Cuiaba, MT, which was
located about 1500 miles from Manaus city. CNAS levels were
also evaluated in plasma samples from a small group of P.
falciparum patients (n=9; age range, 18–52 yrs.). Plasma samples
were isolated immediately after blood sampling and stored at
280uC until use.
Malaria vivax clinical score
Since at present no clear criteria define vivax malaria severity,
the present study used the World Health Organization standard
criteria built for P. falciparum malaria [50]. One patient (Pv_04,
Table 1) presented clinical signs of severe malaria according to
the WHO criteria. This patient presented with hyperbilirrubi-
nemia (total bilirubin=4.3 mg/dL) and acute renal failure
(creatinin=2.3 mg/dL), and other common infectious diseases
were ruled out during his hospitalization. To define different
degrees of morbidity for the remaining P. vivax malaria patients,
we adapted the criteria originally described by Karunaweera et
al [56], and previously validated in the Amazon area [57].
Briefly, the occurrence of fever at the time of blood collection
and other 8 signs and/or symptoms that commonly accompany
a malarial infection - headache, chills, myalgia, nausea,
vomiting and diarrhea - were addressed into the questionnaire
applied to each patient. Additionally, hematological parameters
were also included in the score calculation: white blood cells
(WBC), red blood cells (RBC) and platelets counts, hemoglobin
and hematocrit levels (Table 1). Numerical scores of 0 or 1 were
assigned to clinical and hematological parameters reported as
a b s e n t( o rw i t h i nn o r m a lr a n g e )o rp r e s e n t( o ro u t s i d en o r m a l
range), respectively. For those 15 parameters analyzed, the sum
of scores provides the patient’s final clinical score, as shown in
Table S1 (supporting information). This semi quantitative
clinical assessment enabled numerical comparisons between
the plasma CNAs levels and the clinical spectrum of vivax
malaria.
Purification and quantification of CNAs from plasma
Cell-free circulating nucleic acids (CNAs) were isolated from
plasma from P. vivax patients or healthy donors with QIAamp
Circulating Nucleic Acid Kit (Qiagen, CA, US) according to the
manufacturer’s instructions. Two different methodologies were
used to quantify CNAs levels in plasma: (i) amplification of the
genomic sequence of the human telomerase reverse transcriptase
(hTERT), an ubiquitous single copy gene mapped on 5p 15.33,
used here as a marker of the total amount of DNA present in
plasma samples. For that, we used the following specific primers
Fw: 59GGC ACA CGT GGC TTT TCG 39; Rev: 59 GGT GAA
CCT GCT AAG TTT ATG CAA 39, previously described [58].
To normalize the amount of DNA in plasma samples, 5 ng of
Salmon Sperm DNA solution (Invitrogen, CA, USA) were spiked
into plasma samples before purification of CNAs. The genomic
sequence of the chum salmon (Oncorhynchus keta) Y-chromosome
specific marker was amplified in parallel with hTERT using the
specific primers: Fw: 59 AGG CAA CCC TTG CTC GAA TT 39;
Rev 59 TGG GCA CAT GGC TTA CCG 39; (ii) total dsDNA
levels in plasmas were also quantified fluorometrically using the
Quant-iTTM Pico Green Reagent (Molecular Probes, Nether-
lands) according to the manufacturer’s instructions.
To identify parasite derived sequences in plasma samples from
infected patients the following primer pair Fw: 59 CAA CAG GTC
CTT CAC GCT TAG TG 39; Rev: 59 CGA CAG CAC CAT
TGG CG 39 was designed based on the P. vivax genomic sequence
[59] retrieved from PlasmoDB version 6.4 (http://plasmodb.org/
plasmo/). The Primer Express software (PE Applied Biosystems)
was used for primer design. Quantitative PCR reactions were
carried out in an ABI Prism 7000 Sequence Detection System
SDS (PE Applied Biosystems, CA, USA). The temperature profile
was 95uC for 10 min followed by 40 cycles of denaturation at
95uC for 15 s and annealing/extension at 60uC for 1 min. The
cycle threshold for DNA quantification was set to 0.2 for all
experiments in this study.
Statistical analysis
Data were analyzed using GraphPad Prism version 5.00 for
Windows (GraphPad Software, CA, US). Differences in the means
were analyzed using two-tailed student’s t test or Mann-Whitney
test when data did not fit a Gaussian distribution. Spearman
nonparametric correlation coefficient was used to analyze the
association between the variables.
Supporting Information
Figure S1 Absolute quantification of hTERT levels in
plasma from P. vivax patients. The human genomic
sequence of hTERT was amplified by PCR using the primers
described in M&M. The concentration of the PCR product was
determined spectrophotometrically using Nanodrop. (A) A stan-
dard curve was built by re-amplifying known amounts of the
hTERT PCR product in 10-fold serial dilutions. (B) Amplification
of hTERT in CNAs samples purified from healthy donors or
malaria patients. (C) Results of interpolated hTERT concentra-
tions in CNAs samples purified from plasma of healthy donors or
malaria patients. Levels are expressed as pg/ml. Differences were
calculated by the Mann-Whitney test. A p value,0.05 was
considered significant.
(TIFF)
Figure S2 Plasma CNAs levels correlates with vivax
thrombocytopenia in a different Brazilian endemic area,
Cuiaba, Mato Grosso. Correlation of plasma CNAs levels with
platelet counts in 14 symptomatic vivax malaria patients attended
at the hospital Julio Muller, Cuiaba, MT. (A) The mean cycle
threshold for hTERT amplification was plotted against the platelet
counts (Pearson r=0.745, p=0.0072). (B) Assessment of CNAs
levels and mean cycle threshold for hTERT amplification in
samples from 10 out of 14 patients who returned after 7–10 days
post treatment.
(TIFF)
Figure S3 Plasma CNAs levels correlates with throm-
bocytopenia in P. falciparum patients. CNAs levels were
assessed in plasma from 9 samples from P. falciparum patients and
correlated with (A) their platelet counts and (B) body temperature
measured at the time of blood collection. Fluorometric dsDNA
measurement by PicoGreen and qPCR amplification of hTERT
genomic sequence were used for comparisons.
(TIFF)
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